Pigmentation-pathway peptide compounds.

Tanning and pigmentation research peptides are melanocortin receptor agonists (alpha-MSH analogs) studied in preclinical research models for their effects on melanogenesis signaling. The Nexus catalog includes 2 compounds in this category — examples: MT-1, MT-2 (Melanotan 2 Acetate). Supplied for in-vitro research use only.

The tanning and pigmentation category contains melanocortin-pathway research products. Nexus keeps this compact group separate from cosmetic and skin peptides because receptor context, compound identity, and analytical classification differ.

The category includes MT-1 and MT-2 / Melanotan 2. Copy remains research-grade and does not provide consumer-use guidance or appearance claims.

Melanocortin research products are compared by analog identity, receptor pathway, sequence, and structural differences. Because the category is small, the page prioritizes clear distinctions between the two records rather than broad outcome claims.

Nexus product pages keep the emphasis on variant size, available lot/COA context, and research-only positioning. This helps researchers distinguish catalog identity from cosmetic, personal-use, or appearance-oriented interpretations.

Nexus uses conservative labeling, lot-specific certificate status, and product-specific pages for each melanocortin record. Finalized records display only fields present in their source files; pending records expose no assay values.

Compounds in this category are studied in preclinical research models examining the melanocortin pathway — particularly melanocortin-1 receptor (MC1R) pharmacology for pigmentation research and melanocortin-3/4 receptor pharmacology for broader research applications. Common research applications include MT-1 (Nle4-DPhe7-α-MSH / melanotan I / afamelanotide research analog) research on MC1R agonism, and MT-2 (melanotan II) research as a broader melanocortin agonist with activity across MC1R, MC3R, MC4R, and MC5R.

The two compounds in this category are both α-MSH analogs but differ in receptor selectivity: MT-1 is the more selective MC1R-focused research analog; MT-2 is the broader melanocortin agonist with multi-receptor activity. The structural difference is small (a cyclized variant in MT-2 versus the linear MT-1) but produces meaningful research-context differences in receptor pharmacology.

MT-1 and MT-2 should be evaluated as separate compound records. PT-141 and KPV may appear in adjacent melanocortin literature, but their presence in other Nexus categories does not make them interchangeable with MT-1 or MT-2 and does not constitute a pairing recommendation. Researchers should compare sequence, receptor context, and source documentation independently.

Analytical methods vary by compound, format, and named lot. A finalized lot record publishes only the methods, fields, and results present in its source document. A pending certificate state exposes no assay values; no category-level method panel, purity threshold, or release conclusion is implied.